Axsome Therapeutics (NASDAQ: AXSM) reported Q2 EPS of ($1.67), $0.36 worse than the analyst estimate of ($1.31). Revenue for the quarter came in at $87.2 million versus the consensus estimate of $86.66 million.

Financial Guidance

Axsome believes that its current cash is sufficient to fund anticipated operations into cash flow positivity, based on the current operating plan.

For earnings history and earnings-related data on Axsome Therapeutics (AXSM) click here.